Pioglitazone does not enhance the effectiveness of lifestyle modification in preventing conversion of impaired glucose tolerance to diabetes in Asian Indians: results of the Indian Diabetes Prevention Programme-2 (IDPP-2) - PubMed (original) (raw)

. 2009 Jun;52(6):1019-26.

doi: 10.1007/s00125-009-1315-x. Epub 2009 Mar 10.

Affiliations

• PMID: 19277602
• DOI: 10.1007/s00125-009-1315-x

Pioglitazone does not enhance the effectiveness of lifestyle modification in preventing conversion of impaired glucose tolerance to diabetes in Asian Indians: results of the Indian Diabetes Prevention Programme-2 (IDPP-2)

A Ramachandran et al. Diabetologia. 2009 Jun.

Abstract

Aims/hypothesis: The objective of this prevention programme was to study whether combining pioglitazone with lifestyle modification would enhance the efficacy of lifestyle modification in preventing type 2 diabetes in Asian Indians with impaired glucose tolerance.

Methods: In a community-based, placebo-controlled 3 year prospective study, 407 participants with impaired glucose tolerance (mean age 45.3 +/- 6.2 years, mean BMI 25.9 +/- 3.3 kg/m(2)) were sequentially grouped to receive either: lifestyle modification plus pioglitazone, 30 mg (n = 204) or lifestyle modification plus placebo (n = 203). The participants and investigators were blinded to the assignment. The primary outcome was development of diabetes.

Results: At baseline, both groups had similar demographic, anthropometric and biochemical characteristics. At year 3, the response rate was 90.2%. The cumulative incidence of diabetes was 29.8% with pioglitazone and 31.6% with placebo (unadjusted HR 1.084 [95% CI 0.753-1.560], p = 0.665). Normoglycaemia was achieved in 40.9% and 32.3% of participants receiving pioglitazone and placebo, respectively (p = 0.109). In pioglitazone group, two deaths and two non-fatal hospitalisations occurred due to cardiac problems; in the placebo group there were two occurrences of cardiac disease.

Conclusions/interpretation: Despite good adherence to lifestyle modification and drug therapy, no additional effect of pioglitazone was seen above that achieved with placebo. The effectiveness of the intervention in both groups was comparable with that of lifestyle modification alone, as reported from the Indian Diabetes Prevention Programme-1. The results are at variance with studies that showed significant relative risk reduction in conversion to diabetes with pioglitazone in Americans with IGT. An ethnicity-related difference in the action of pioglitazone in non-diabetic participants may be one explanation.

Trial registration: ClinicalTrials.gov NCT00276497 FUNDING: This study was funded by the India Diabetes Research Foundation.

PubMed Disclaimer

Similar articles

• The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).
  Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V; Indian Diabetes Prevention Programme (IDPP). Ramachandran A, et al. Diabetologia. 2006 Feb;49(2):289-97. doi: 10.1007/s00125-005-0097-z. Epub 2006 Jan 4. Diabetologia. 2006. PMID: 16391903 Clinical Trial.
• Rationale, Design, and Baseline Characteristics of Beijing Prediabetes Reversion Program: A Randomized Controlled Clinical Trial to Evaluate the Efficacy of Lifestyle Intervention and/or Pioglitazone in Reversion to Normal Glucose Tolerance in Prediabetes.
  Luo Y, Paul SK, Zhou X, Chang C, Chen W, Guo X, Yang J, Ji L, Wang H. Luo Y, et al. J Diabetes Res. 2017;2017:7602408. doi: 10.1155/2017/7602408. Epub 2017 Jan 12. J Diabetes Res. 2017. PMID: 28168204 Free PMC article. Clinical Trial.
• Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP-1 and IDPP-2).
  Ramachandran A, Arun N, Shetty AS, Snehalatha C. Ramachandran A, et al. Diabetes Care. 2010 Oct;33(10):2164-8. doi: 10.2337/dc09-1150. Epub 2010 Jun 2. Diabetes Care. 2010. PMID: 20519663 Free PMC article. Clinical Trial.
• Effects of dietary and physical activity interventions on the risk of type 2 diabetes in South Asians: meta-analysis of individual participant data from randomised controlled trials.
  Jenum AK, Brekke I, Mdala I, Muilwijk M, Ramachandran A, Kjøllesdal M, Andersen E, Richardsen KR, Douglas A, Cezard G, Sheikh A, Celis-Morales CA, Gill JMR, Sattar N, Bhopal RS, Beune E, Stronks K, Vandvik PO, van Valkengoed IGM. Jenum AK, et al. Diabetologia. 2019 Aug;62(8):1337-1348. doi: 10.1007/s00125-019-4905-2. Epub 2019 Jun 15. Diabetologia. 2019. PMID: 31201437 Review.

Cited by

• Nonlinear association between remnant cholesterol and reversion from impaired fasting glucose to normoglycemia: a multicenter cohort study.
  Kong L, Wu Y, Yang H, Guo M, Zhong Y, Li J, Wu S, Xiong Z. Kong L, et al. Lipids Health Dis. 2024 Sep 19;23(1):303. doi: 10.1186/s12944-024-02286-8. Lipids Health Dis. 2024. PMID: 39300559 Free PMC article.
• Physical Activity, Cardiovascular Status, Mortality, and Prediabetes in Hispanic and Non-Hispanic Adults.
  Alver SK, Pan S, Mossavar-Rahmani Y, Sotres-Alvarez D, Evenson KR, Floyd JS, Xanthakis V, Lin J, Cuthbertson C, Gallo LC, Cai J, Penedo FJ, Llabre MM, Matsushita K, Talavera GA, Pirzada A, Spartano N, Daviglus ML, Vasan RS, Kaplan RC. Alver SK, et al. JAMA Netw Open. 2024 Jun 3;7(6):e2415094. doi: 10.1001/jamanetworkopen.2024.15094. JAMA Netw Open. 2024. PMID: 38842811 Free PMC article.
• Evaluation of the role of atherogenic index of plasma in the reversion from Prediabetes to normoglycemia or progression to Diabetes: a multi-center retrospective cohort study.
  Yang H, Kuang M, Yang R, Xie G, Sheng G, Zou Y. Yang H, et al. Cardiovasc Diabetol. 2024 Jan 6;23(1):17. doi: 10.1186/s12933-023-02108-8. Cardiovasc Diabetol. 2024. PMID: 38184569 Free PMC article.
• Impact of individual and environmental factors on dietary or lifestyle interventions to prevent type 2 diabetes development: a systematic review.
  Bodhini D, Morton RW, Santhakumar V, Nakabuye M, Pomares-Millan H, Clemmensen C, Fitzpatrick SL, Guasch-Ferre M, Pankow JS, Ried-Larsen M, Franks PW; ADA/EASD PMDI; Tobias DK, Merino J, Mohan V, Loos RJF. Bodhini D, et al. Commun Med (Lond). 2023 Oct 5;3(1):133. doi: 10.1038/s43856-023-00363-0. Commun Med (Lond). 2023. PMID: 37794109 Free PMC article.

References

1. 1. Diabetologia. 2004 May;47(5):860-5 - PubMed
2. 1. Diabetes. 2006 Feb;55(2):517-22 - PubMed
3. 1. Diabetes Res Clin Pract. 2004 Sep;65(3):189-95 - PubMed
4. 1. Diabetologia. 2008 Jan;51(1):8-11 - PubMed
5. 1. Diabetologia. 2006 Feb;49(2):289-97 - PubMed

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Springer

• Medical

  • MedlinePlus Health Information